TRIB vs. ABIO, ICCC, AWH, OCX, CDIO, BMRA, MYMD, VRAX, NAVB, and IDXX
Should you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include ARCA biopharma (ABIO), ImmuCell (ICCC), Aspira Women's Health (AWH), OncoCyte (OCX), Cardio Diagnostics (CDIO), Biomerica (BMRA), MyMD Pharmaceuticals (MYMD), Virax Biolabs Group (VRAX), Navidea Biopharmaceuticals (NAVB), and IDEXX Laboratories (IDXX). These companies are all part of the "diagnostic substances" industry.
ARCA biopharma (NASDAQ:ABIO) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership.
56.4% of ARCA biopharma shares are owned by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are owned by institutional investors. 30.9% of ARCA biopharma shares are owned by insiders. Comparatively, 8.2% of Trinity Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Trinity Biotech received 201 more outperform votes than ARCA biopharma when rated by MarketBeat users. Likewise, 71.37% of users gave Trinity Biotech an outperform vote while only 41.98% of users gave ARCA biopharma an outperform vote.
ARCA biopharma has a net margin of 0.00% compared to ARCA biopharma's net margin of -37.96%. ARCA biopharma's return on equity of 0.00% beat Trinity Biotech's return on equity.
In the previous week, Trinity Biotech had 5 more articles in the media than ARCA biopharma. MarketBeat recorded 6 mentions for Trinity Biotech and 1 mentions for ARCA biopharma. ARCA biopharma's average media sentiment score of 0.73 beat Trinity Biotech's score of 0.00 indicating that Trinity Biotech is being referred to more favorably in the news media.
ARCA biopharma has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.
ARCA biopharma has higher earnings, but lower revenue than Trinity Biotech. ARCA biopharma is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Trinity Biotech beats ARCA biopharma on 9 of the 14 factors compared between the two stocks.
Get Trinity Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Trinity Biotech Competitors List
Related Companies and Tools
